A New Grand Challenge in Rhinology: An Intranasal COVID Vaccine

A New Grand Challenge in Rhinology: An Intranasal COVID Vaccine

Bibliographic Details
Main Author:	Glenis Kathleen Scadding
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-05-01
Series:	Frontiers in Allergy
Subjects:	SARS-CoV-2 COVID-19 systemic vaccines intranasal vaccine IgA
Online Access:	https://www.frontiersin.org/articles/10.3389/falgy.2022.881118/full

Similar Items

Editorial: Insights in rhinology: 2021/22
by: Peter Kenneth Smith, et al.
Published: (2023-06-01)

Intranasal COVID-19 vaccines: From bench to bed
by: Aqu Alu, et al.
Published: (2022-02-01)

Oral and intranasal vaccines against SARS‐CoV‐2: Current progress, prospects, advantages, and challenges
by: Sanchita Kar, et al.
Published: (2022-04-01)

Identifying COVID-19 Infections From a Vaccinated Population Using Specific IgA Antibody Test
by: Zhangkai J. Cheng, et al.
Published: (2022-01-01)

Intranasal Administration of Recombinant Newcastle Disease Virus Expressing SARS-CoV-2 Spike Protein Protects hACE2 TG Mice against Lethal SARS-CoV-2 Infection
by: Deok-Hwan Kim, et al.
Published: (2024-08-01)

COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges
by: Kuldeep Dhama, et al.
Published: (2022-11-01)

Twelve-Month Longitudinal Serology in SARS-CoV-2 Naïve and Experienced Vaccine Recipients and Unvaccinated COVID-19-Infected Individuals
by: Zion Congrave-Wilson, et al.
Published: (2022-05-01)

Safety and Immunogenicity of the Intranasal Vaccine Candidate Mambisa and the Intramuscular Vaccine Abdala Used as Booster Doses for COVID-19 Convalescents: A Randomized Phase 1–2 Clinical Trial
by: Gilda Lemos-Pérez, et al.
Published: (2024-09-01)

Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates
by: Amir I. Tukhvatulin, et al.
Published: (2022-12-01)

Significant increase in anti-SARS-CoV-2 antibodies after administration of heterologous mRNA-based vaccine booster in individuals receiving two doses of inactivated COVID-19 vaccine: A single-center study in healthcare workers in Jakarta, Indonesia
by: Wuryantari Setiadi, et al.
Published: (2023-11-01)

Oral Bacteria Combined with an Intranasal Vaccine Protect from Influenza A Virus and SARS-CoV-2 Infection
by: Minami Nagai, et al.
Published: (2021-08-01)

IgA nephropathy after COVID-19 vaccination and analysis of reported cases
by: Akira Mima, et al.
Published: (2023-06-01)

IgA quantification as a good predictor of the neutralizing antibodies levels after vaccination against SARS-CoV-2
by: Lorena O. Fernandes-Siqueira, et al.
Published: (2022-11-01)

Intranasal Immunization with Liposome-Displayed Receptor-Binding Domain Induces Mucosal Immunity and Protection against SARS-CoV-2
by: Wei-Chiao Huang, et al.
Published: (2022-09-01)

Nasal and Salivary Mucosal Humoral Immune Response Elicited by mRNA BNT162b2 COVID-19 Vaccine Compared to SARS-CoV-2 Natural Infection
by: Mariapia Guerrieri, et al.
Published: (2021-12-01)

Characteristics of Vaccine- and Infection-Induced Systemic IgA Anti-SARS-CoV-2 Spike Responses
by: Natasha J. Norton, et al.
Published: (2023-09-01)

Development of an Oral IgA Response against SARS-CoV-2 Following Immunization with Different COVID-19 Vaccines
by: Irene Soffritti, et al.
Published: (2023-11-01)

Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial
by: Meera Madhavan, et al.
Published: (2022-11-01)

Saliva is suitable for SARS-CoV-2 antibodies detection after vaccination: A rapid systematic review
by: Eliete Neves Silva Guerra, et al.
Published: (2022-09-01)

An intranasal vaccine targeting the receptor binding domain of SARS-CoV-2 elicits a protective immune response
by: Li Chen, et al.
Published: (2022-11-01)

Immunogenicity and Safety of a Combined Intramuscular/Intranasal Recombinant Spike Protein COVID-19 Vaccine (RCP) in Healthy Adults Aged 18 to 55 Years Old: A Randomized, Double-Blind, Placebo-Controlled, Phase I Trial
by: Masoud Solaymani Dodaran, et al.
Published: (2023-02-01)

Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a heterologous prime-boost strategy with COVAXIN (BBV152)
by: Raju Sunagar, et al.
Published: (2022-12-01)

Editorial: 2022 in review: rhinology
by: Diego M. Conti, et al.
Published: (2024-04-01)

Intranasal Single-Replication Influenza Vector Induces Cross-Reactive Serum and Mucosal Antibodies against SARS-CoV-2 Variants
by: Michael J. Moser, et al.
Published: (2023-06-01)

Comparison of IgA, IgG, and Neutralizing Antibody Responses Following Immunization With Moderna, BioNTech, AstraZeneca, Sputnik-V, Johnson and Johnson, and Sinopharm’s COVID-19 Vaccines
by: Tomabu Adjobimey, et al.
Published: (2022-06-01)

Rapid increase in salivary IgA and broad recognition of spike protein following SARS-CoV-2 vaccination
by: Kenji Ota, et al.
Published: (2024-01-01)

Dynamics of Anti-SARS-CoV-2 IgA and IgG Responses and Their Protective Effect against Fatal Disease after Booster COVID-19 Vaccination
by: Matthaios Speletas, et al.
Published: (2023-12-01)

Inhalable Vaccines: Can They Help Control Pandemics?
by: Vivek P. Chavda, et al.
Published: (2022-08-01)

Prior COVID-19 Immunization Does Not Cause IgA- or IgG-Dependent Enhancement of SARS-CoV-2 Infection
by: Melyssa Yaugel-Novoa, et al.
Published: (2023-03-01)

Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?
by: Jingjing Zhang, et al.
Published: (2022-12-01)

SARS-CoV-2 spike RBD-specific IgA and IgG antibodies in breast milk after vaccination with the protein subunit vaccine Abdala
by: Maylin Pérez-Bernal, et al.
Published: (2022-12-01)

Intranasal boosting with RBD-HR protein vaccine elicits robust mucosal and systemic immune responses
by: Li Chen, et al.
Published: (2024-07-01)

Editorial: Mucosal immunity to HIV and SARS-CoV-2 infection and vaccination
by: Morgane Bomsel, et al.
Published: (2023-06-01)

Longitudinal IgA and IgG Response, and ACE2 Binding Blockade, to Full-Length SARS-CoV-2 Spike Protein Variants in a Population of Black PLWH Vaccinated with ChAdOx1 nCoV-19
by: Muneerah Smith, et al.
Published: (2023-02-01)

Mucosal and Systemic Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination Determined by Severity of Primary Infection
by: Mohammad M. Sajadi, et al.
Published: (2022-12-01)

The impact of vaccine type and booster dose on the magnitude and breadth of SARS-CoV-2-specific systemic and mucosal antibodies among COVID-19 vaccine recipients
by: Hoi-Wah Tsoi, et al.
Published: (2024-08-01)

Harnessing Nasal Immunity with IgA to Prevent Respiratory Infections
by: John Joseph
Published: (2022-10-01)

Intranasal inoculation of female BALB/c mice with replication-deficient human adenovirus type 5 expressing SARS-CoV‐2 nucleocapsid protein aggravates lung pathology upon re-encountering the antigen
by: Junxia Cao, et al.
Published: (2023-10-01)

Intranasal Prime–Boost with Spike Vectors Generates Antibody and T-Cell Responses at the Site of SARS-CoV-2 Infection
by: Muriel Metko, et al.
Published: (2024-10-01)

Sibling cases of gross hematuria and newly diagnosed IgA nephropathy following SARS-CoV-2 vaccination
by: Yuri Uchiyama, et al.
Published: (2022-06-01)